Evidence map›Paper›PMID 40529060›Full record

ArticleACS medicinal chemistry letters2025

Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype.

Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J L Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal and 5 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Effect of Ammonia onAntioxidants (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marta ClarianoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.ORCID https://orcid.org/0000-0002-7644-6290
Diogo NunesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Daniela CanudoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Daniela MaçãsResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Bruno J L CastroResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.ORCID https://orcid.org/0009-0004-1598-5495
Audrey JordaanInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.
Pedro GomesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Anna ContiniDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.
João PerdigãoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Isabel PortugalResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Margarida MadureiraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.
Digby F WarnerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.ORCID https://orcid.org/0000-0002-4146-0930
Marco PieroniDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID https://orcid.org/0000-0001-9190-3712
Maria de Jesus PerryResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.ORCID https://orcid.org/0000-0002-8110-2740
Francisca LopesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisboa, Portugal.ORCID https://orcid.org/0000-0002-5350-147X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), remains the world's most lethal infectious disease, posing an uncontained health challenge. The major hurdles are the long treatments and low patient compliance that leads to the appearance of resistance, as well as the lack of drugs that effectively tackle the latent infections. Herein we report the development of compounds with the ability to target the electron transport chain of Mtb by inhibiting cytochrome

Indexed as

Antituberculosis drugsElectron transport chainMycobacterium tuberculosisTuberculosis

Identifiers

PMID40529060
PMCPMC12169488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.